Search Medical Condition
Please enter condition
Please choose location

Allergy Clinical Trials

A listing of Allergy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (118) clinical trials

Efficacy and Safety Study of RAGWITEK (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

The purpose of this study is to assess the efficacy and safety of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced allergic rhinitis/rhinoconjunctivitis with or without asthma. The primary hypothesis of this study is that administration ...

Phase

Pilot Study on Traditional Chinese Medicine and Food Allergy

The investigators aim to recruit 24 subjects for the present study. Subjects will be randomized into two groups, control group (n=12) and treatment group (n=12). At recruitment all subjects will be required to stop anti-allergic medicines and Chinese medicines as a wash out period for two weeks (week 1 and ...

Phase N/A

Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this study is to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass pollen-induced allergic rhinoconjunctivitis compared to placebo.

Phase

Cesarean Section Study

Effect, tolerance and safety of a supplementation with a probiotic on the risk of gastrointestinal infections, on growth, and on gut microbiota in healthy newborn term infants born by Cesarean section. Exploratory comparison between a probiotic vs. placebo in the formula-fed and in the breastfed feeding groups.

Phase N/A

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

After the screening procedures confirm that eligibility: - The participant will receive a dose of 300mg of omalizumab under the skin every four weeks at three separate visits representing a treatment period of 12 weeks. - During the entire course of the study, the participant will continue receiving their chemotherapy ...

Phase

A Pilot Study of Zavesca in Patients With Pompe Disease and Infusion Associated Reaction

This Study is designed to assess the effects of Zavesca® as immunomodulatory therapy on anti-rhGAA immune responses in patients with Pompe disease, as well as their health and disease progression. Subjects will either receive Zavesca® at 100 mg or 300 mg dosing levels during study participation (n=3 @ 100 mg ...

Phase

Allergy to Neuromuscular Blocking Agents and Pholcodine Exposure

The main objective of this study is to compare pholcodine exposure in patients having presented with a perianaesthetic anaphylactic reaction to a NMBA (cases) to pholcodine exposure in matched anaesthetised patients with injection of NMBA, who did not present with an anaphylactic reaction (controls). The secondary objectives of the study ...

Phase N/A

The Leaky Lung Test

A cohort of subjects with asthma and healthy controls will be exposed to inhaled mannitol according to FDA approved protocols for bronchoprovocation. Mannitol will be measured in the bloodstream and urine and used to determine an airway permeability index. This is a proof of concept study and not a trial ...

Phase N/A

Fel d 1 Peptide Immunotherapy Clinical Trial

Cat-PAD is an experimental cat allergy vaccine and has been studied to determine if it can reduce symptom scores of participants exposed to cat allergen. To study how the vaccine causes changes in the immune system, the researchers plan to evaluate changes in the blood (genes and proteins) and urine ...

Phase

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

This exploratory study consists of four visits to the investigator site post screening: at Weeks 0 (baseline), 2, 6 and 8 (Figure 1). At the first visit (baseline), patients who have met the screening eligibility criteria will be started on a stable TCS regimen for a total of two weeks. ...

Phase